top of page

Bella One PAP  


The Bella One PAP is a FDA-approved test to screen  for presence of human papillomavirus (HPV) DNA along with genotyping for high risk strains of HPV. The molecular panel also screens for presence of sexually transmitted infections and bacterial vaginosis pathogens that pose a threat to women's health

Bella One PAP Panel Menu

Performance: 100% sensitivity and 99.8% specificity 
Sample Type: Cervical Vaginal

Methodology: Real-Time PCR

STI Molecular Assay Panel

BV Assay Molecular Panel

Chlamydia trachomatis 

Trichomonas vaginalis

Neisseria gonorrhoeae 

Mycoplasma genitalium 

Mycoplasma hominis

Ureaplasma urealyticum

Ureaplasma parvum 

Herpes simplex virus Type 1

Herpes simplex virus Type 2

Gardnerella vaginalis

Prevotella bivia 

Atopobium vaginae

Mobiluncus curtisii

Bacteroides fragilis

Megasphaera Type 1 


Bacterial vaginosis 

PCG dots _edited.jpg

Boost effectiveness of patient testing


Awareness about the link between HPV and cervical cancer has grown exponentially – leading to earlier detection and prevention. The CDC estimates that up to 93 percent of cervical cancers can be prevented. And yet, 33 percent of the 12,000 women who are diagnosed annually will die. 

Why Bella One PAP

The Bella One PAP screens for presence of Human Papilloma Virus (HPV) DNA  as well as precancerous cells  to determine whether a woman is at high-risk for developing cervical precancerous or cancerous conditions. – in addition Bella One Pap is design to test for a host of other infectious gynecological conditions.

Ultra Solutions

Molecular Reporting 

Screenshot 2022-12-15 at 9.16.23 AM.png
Screenshot 2022-12-15 at 9.16.12 AM.png

For negative results PCG Molecular will send your patients an email on your behalf within 24 hours if patient results are negative for “watch” or high risk results. Being placed on a watch is no reason for patients to panic. It doesn’t mean they have cervical cancer or that they will ever get it. All it means is that we need to watch their cases more closely. We will send you a report and give you a sample letter to send to your patients that communicates the results and what next steps to follow. for positive results. You will receive a detailed report for those patients that test positive for oncogenic viral related sexually transmitted infections. These patients may require additional tests after treatment, along with a personal call. We can advise you of next steps and referrals if you need them. 

bottom of page